ATE441710T1 - Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen - Google Patents

Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen

Info

Publication number
ATE441710T1
ATE441710T1 AT04706034T AT04706034T ATE441710T1 AT E441710 T1 ATE441710 T1 AT E441710T1 AT 04706034 T AT04706034 T AT 04706034T AT 04706034 T AT04706034 T AT 04706034T AT E441710 T1 ATE441710 T1 AT E441710T1
Authority
AT
Austria
Prior art keywords
hif
inhibit
expression level
antisense oligonucleotides
cell lines
Prior art date
Application number
AT04706034T
Other languages
English (en)
Inventor
Heejeong Yoon
Lingjun Mao
Young Lee
Chang-Ho Ahn
Xiaoming Jiang
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Corp filed Critical Rexahn Corp
Priority claimed from PCT/US2004/002344 external-priority patent/WO2004066949A2/en
Application granted granted Critical
Publication of ATE441710T1 publication Critical patent/ATE441710T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04706034T 2003-01-31 2004-01-28 Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen ATE441710T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44436703P 2003-01-31 2003-01-31
PCT/US2004/002344 WO2004066949A2 (en) 2003-01-28 2004-01-28 Antisense oligonucleotides that inhibit expression of hif-1

Publications (1)

Publication Number Publication Date
ATE441710T1 true ATE441710T1 (de) 2009-09-15

Family

ID=35261932

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04706034T ATE441710T1 (de) 2003-01-31 2004-01-28 Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen

Country Status (9)

Country Link
US (1) US7205283B2 (de)
EP (1) EP1601325B1 (de)
KR (1) KR101069521B1 (de)
CN (1) CN100471862C (de)
AT (1) ATE441710T1 (de)
BR (1) BRPI0407070A (de)
CA (1) CA2513398C (de)
DE (1) DE602004022921D1 (de)
ES (1) ES2333794T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
WO2005032486A2 (en) * 2003-10-02 2005-04-14 Duke University A NOVEL SIRNA-BASED APPROACH TO TARGET THE HIF-α FACTOR FOR GENE THERAPY
US7618947B2 (en) * 2004-08-25 2009-11-17 Isis Pharmaceuticals, Inc. Modulation of HIF-1 beta expression
US20100074897A1 (en) * 2006-12-01 2010-03-25 University Of Utah Research Foundation Methods and Compositions related to HIF-1 alpha
US20080318241A1 (en) * 2007-06-18 2008-12-25 The Regents Of The University Of Michigan Methods and Systems for Detecting Antiangiogenesis
US20110294868A1 (en) 2010-04-29 2011-12-01 Monia Brett P Modulation of transthyretin expression
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
CN105163721B (zh) * 2012-05-23 2018-05-22 俄亥俄州立大学 脂质纳米颗粒组合物以及制备和使用其的方法
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
WO2002034291A2 (en) * 2000-10-26 2002-05-02 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
SI2264172T1 (sl) * 2002-04-05 2017-12-29 Roche Innovation Center Copenhagen A/S Oligomerne spojine za modulacijo izražanja HIF-1alfa
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression

Also Published As

Publication number Publication date
CA2513398C (en) 2013-09-10
KR101069521B1 (ko) 2011-09-30
US20040152655A1 (en) 2004-08-05
US7205283B2 (en) 2007-04-17
CA2513398A1 (en) 2004-08-12
EP1601325A4 (de) 2008-02-20
BRPI0407070A (pt) 2006-01-24
EP1601325B1 (de) 2009-09-02
CN100471862C (zh) 2009-03-25
KR20050103476A (ko) 2005-10-31
ES2333794T3 (es) 2010-03-01
CN1809583A (zh) 2006-07-26
EP1601325A2 (de) 2005-12-07
DE602004022921D1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
MXPA03003151A (es) Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
NL1025527A1 (nl) Triazoolverbindingen die nuttig zijn in therapie.
WO2007076423A3 (en) INHIBITORS OF Akt ACTIVITY
TW200612918A (en) Lonidamine analogs
EP1290005A4 (de) Vegf-modulierte gene und verfahren, die diese verwenden
NO20052701D0 (no) Mikrobiocidiske stoffer.
ATE441710T1 (de) Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
AU300372S (en) Personal care product
WO2004016215A3 (en) Use of antisense oligonucleotides to inhibit the expression of akt-1
NO20054053D0 (no) Triazolforbindelser anvendbare i terapi.
WO2004066949A8 (en) Antisense oligonucleotides that inhibit expression of hif-1
PL1713438T3 (pl) Mydło lecznicze
CA102731S (en) Fragrance dispenser
IS7538A (is) Prógestagena skammta einingar.
ITMI20032037A1 (it) Supporto del cruscotto.
NO20053189D0 (no) HVC-kombinasjonsterapi.
ATE428786T1 (de) Antisense-oligonukleotid mit antikrebsaktivität
FR2858695B1 (fr) Calculateur personnel.
CA105222S (en) Lavatory device
BR0318204A (pt) uso de nucleosìdeos 5-substituìdos
UY29136A1 (es) Uso de epotilonas en el tratamiento de metastasis osea
BR8202549Y1 (pt) disposição introduzida em suporte para chuveiros.
ITRM20020372A1 (it) Metodo di distribuzione di titoli con accredito differito, in particolare per ricariche telefoniche.
ES1053847Y (es) Perfeccionamientos introducidos en carteras.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties